**Supplementary Fig. 13. Forest plot of serious adverse events associated with SOF-based DAA treatment with or without RBV in patients with decompensated hepatitis C cirrhosis.** The SAEs associated with SOF-based DAA treatment were increased when RBV was added: 24.9% (95% CI: 16.3–34.7) vs. 12.8 (95% CI: 7.5–19.1), *p*=0.0255. SOF, sofosbuvir; RBV, ribavirin; SVR, sustained virological response; SAE, serious adverse events.

